<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597633</url>
  </required_header>
  <id_info>
    <org_study_id>MDRCHB</org_study_id>
    <nct_id>NCT03597633</nct_id>
  </id_info>
  <brief_title>Tenofovir Combination or Mono-therapy for MDR CHB</brief_title>
  <official_title>Tenofovir-based Combination Therapy or Monotherapy for Multi-drug Resistant Chronic Hepatitis B; Real World Data From Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHA University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soon Chun Hyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of multidrug resistant (MDR) chronic hepatitis B (CHB) is still a challenging
      issue. Hence, the investigators will perform a multicenter prospective cohort study for the
      evaluation of tenofovir disoproxil fumarate (TDF)-based therapy for MDR CHB at real life
      settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria were CHB patients with resistance to more than two classes of
      nucleos(t)ide analogues (NA) and hepatitis B virus (HBV) DNA level ≥200 IU/mL.

      Patients will receive either TDF-base combination therapy or TDF monotherapy. The primary end
      point is virologic response (VR) defined by an undetectable HBV DNA (&lt;20 IU/mL) at month 36.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">June 1, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Virologic Response</measure>
    <time_frame>36 months</time_frame>
    <description>undetectable HBV DNA (&lt;20 IU/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic Response</measure>
    <time_frame>60 months</time_frame>
    <description>undetectable HBV DNA (&lt;20 IU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean HBV DNA</measure>
    <time_frame>36 months, 60 months</time_frame>
    <description>mean HBV DNA levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT normalization</measure>
    <time_frame>36 months, 60 months</time_frame>
    <description>rates of ALT normalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B e antigen (HBeAg) seroconversion</measure>
    <time_frame>36 months, 60 months</time_frame>
    <description>rates of Hepatitis B e antigen (HBeAg) seroconversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>virologic breakthrough</measure>
    <time_frame>36 months, 60 months</time_frame>
    <description>Incidence of virologic breakthrough defined by increase of HBV DNA more than 1 log IU/mL from nar dir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic resistance</measure>
    <time_frame>36 months, 60 months</time_frame>
    <description>Detection of previously known mutations to be resistant to the drugs being administered.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse event</measure>
    <time_frame>36 months, 60 months</time_frame>
    <description>Any untoward event related or not related to the study medication</description>
  </other_outcome>
  <enrollment type="Actual">236</enrollment>
  <condition>Chronic Hepatitis b With Multidrug Resistance</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis B patients with multiple drug resistance.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CHB patients with:

               1. documented HBsAg positivity at least 6 months before enrollment

               2. age &gt;18 years old,

               3. confirmed genotypic resistance to more than two classes of NAs

               4. HBV DNA level ≥ 200 IU/mL

               5. compensated liver diseases (defined by Child-Pugh-Turcotte score &lt;7; prothrombin
                  time &lt;3 seconds above upper limit of normal or international normalized ratio
                  &lt;1.5; serum albumin &gt;3 g/dL; total bilirubin &lt;2.5 mg/dL; no history of
                  esophago-gastric variceal bleeding, ascites, over hepatic encephalopathy)

               6. willingness to give an informed consent.

        Exclusion Criteria:

          1. laboratory abnormalities of low serum phosphorous level &lt;2.0 mEq/dL, elevated serum
             creatinine &gt;1.5 mg/dL, decreased creatinine clearance rate &lt;50 mL/min, absolute
             neutrophil count &lt;1000 cell/mL, or low hemoglobin level &lt;10 g/dL (if female, &lt;9 g/dL)

          2. no definite evidence of genotypic resistance

          3. positive antibody test for hepatitis C virus, hepatitis D virus, or human
             immunodeficiency virus

          4. HCC

          5. a proof of pregnant or lactating women

          6. evidence of active alcohol consumption (140 g per a week for men and 70 g per a week
             for women)

          7. any untreated malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Hyung Joon Yim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Confidential</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

